ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – Here’s Why

ImmuCell Corporation (NASDAQ:ICCC) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.11 and traded as high as $6.45. ImmuCell shares last traded at $6.44, with a volume of 2,936 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of ImmuCell from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, February 24th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, ImmuCell has a consensus rating of “Hold”.

ImmuCell Price Performance

The firm has a market cap of $58.28 million, a PE ratio of -58.54 and a beta of 0.27. The firm’s fifty day simple moving average is $6.40 and its two-hundred day simple moving average is $6.11. The company has a quick ratio of 1.76, a current ratio of 4.21 and a debt-to-equity ratio of 0.27.

Institutional Investors Weigh In On ImmuCell

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Steadtrust LLC purchased a new position in shares of ImmuCell in the third quarter valued at about $198,000. Mesirow Financial Investment Management Inc. raised its stake in ImmuCell by 199.6% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 24,303 shares during the period. Finally, Geode Capital Management LLC raised its stake in ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 2,907 shares during the period. 13.47% of the stock is owned by institutional investors.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.